658 related articles for article (PubMed ID: 25751127)
1. The development of animal infection models and antifungal efficacy assays against clinical isolates of Trichosporon asahii, T. asteroides and T. inkin.
Mariné M; Bom VL; de Castro PA; Winkelstroter LK; Ramalho LN; Brown NA; Goldman GH
Virulence; 2015; 6(5):476-86. PubMed ID: 25751127
[TBL] [Abstract][Full Text] [Related]
2. Species distribution and antifungal susceptibility of 358 Trichosporon clinical isolates collected in 24 medical centres.
Francisco EC; de Almeida Junior JN; de Queiroz Telles F; Aquino VR; Mendes AVA; de Andrade Barberino MGM; de Tarso O Castro P; Guimarães T; Hahn RC; Padovan ACB; Chaves GM; Colombo AL
Clin Microbiol Infect; 2019 Jul; 25(7):909.e1-909.e5. PubMed ID: 30991116
[TBL] [Abstract][Full Text] [Related]
3. Multiple species of Trichosporon produce biofilms highly resistant to triazoles and amphotericin B.
Iturrieta-González IA; Padovan AC; Bizerra FC; Hahn RC; Colombo AL
PLoS One; 2014; 9(10):e109553. PubMed ID: 25360765
[TBL] [Abstract][Full Text] [Related]
4. Breakthrough Trichosporon asahii fungemia in neutropenic patient with acute leukemia while receiving caspofungin.
Bayramoglu G; Sonmez M; Tosun I; Aydin K; Aydin F
Infection; 2008 Feb; 36(1):68-70. PubMed ID: 17882360
[TBL] [Abstract][Full Text] [Related]
5. Molecular characterisation and antifungal susceptibility of clinical Trichosporon isolates in India.
Rastogi V; Honnavar P; Rudramurthy SM; Pamidi U; Ghosh A; Chakrabarti A
Mycoses; 2016 Aug; 59(8):528-34. PubMed ID: 27144725
[TBL] [Abstract][Full Text] [Related]
6. In vitro combined activity of amphotericin B, caspofungin and voriconazole against clinical isolates of Trichosporon asahii.
Li H; Lu Q; Wan Z; Zhang J
Int J Antimicrob Agents; 2010 Jun; 35(6):550-2. PubMed ID: 20202797
[TBL] [Abstract][Full Text] [Related]
7. Molecular Identification, Genotyping, Phenotyping, and Antifungal Susceptibilities of Medically Important Trichosporon, Apiotrichum, and Cutaneotrichosporon Species.
do Espírito Santo EPT; Monteiro RC; da Costa ARF; Marques-da-Silva SH
Mycopathologia; 2020 Apr; 185(2):307-317. PubMed ID: 31776790
[TBL] [Abstract][Full Text] [Related]
8. In vitro activities of antifungal combinations against biofilms and planktonic forms of clinical Trichosporon asahii isolates.
Liao Y; Yang S; Cong L; Lu X; Ao J; Yang R
Antimicrob Agents Chemother; 2014 Dec; 58(12):7615-6. PubMed ID: 25246408
[No Abstract] [Full Text] [Related]
9. Trichosporon asahii causing nosocomial urinary tract infections in intensive care unit patients: genotypes, virulence factors and antifungal susceptibility testing.
Sun W; Su J; Xu S; Yan D
J Med Microbiol; 2012 Dec; 61(Pt 12):1750-1757. PubMed ID: 22956749
[TBL] [Abstract][Full Text] [Related]
10. Isolation and antifungal susceptibility testing of Trichosporon asahii in Ceará, Brazil.
Menezes EA; Marinho JA; Angelo MR; Cunha Mda C; Cunha FA; Vasconcelos Júnior AA
Rev Inst Med Trop Sao Paulo; 2012; 54(1):1-3. PubMed ID: 22370746
[TBL] [Abstract][Full Text] [Related]
11. Head-to-head comparison of inhibitory and fungicidal activities of fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole against clinical isolates of Trichosporon asahii.
Hazirolan G; Canton E; Sahin S; Arikan-Akdagli S
Antimicrob Agents Chemother; 2013 Oct; 57(10):4841-7. PubMed ID: 23877683
[TBL] [Abstract][Full Text] [Related]
12. Antifungal activities of tacrolimus in combination with antifungal agents against fluconazole-susceptible and fluconazole-resistant Trichosporon asahii isolates.
Kubiça TF; Denardi LB; Azevedo MI; Oliveira V; Severo LC; Santurio JM; Alves SH
Braz J Infect Dis; 2016; 20(6):539-545. PubMed ID: 27697432
[TBL] [Abstract][Full Text] [Related]
13. Susceptibilities to amphotericin B, fluconazole and voriconazole of Trichosporon clinical isolates.
Tsai MS; Yang YL; Wang AH; Wang LS; Lu DC; Liou CH; Hsieh LY; Wu CJ; Cheng MF; Shi ZY; Lo HJ
Mycopathologia; 2012 Aug; 174(2):121-30. PubMed ID: 22318636
[TBL] [Abstract][Full Text] [Related]
14. Molecular identification, genotyping, and antifungal susceptibility testing of clinically relevant Trichosporon species from Argentina.
Taverna CG; Córdoba S; Murisengo OA; Vivot W; Davel G; Bosco-Borgeat ME
Med Mycol; 2014 May; 52(4):356-66. PubMed ID: 24682113
[TBL] [Abstract][Full Text] [Related]
15. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
16. MALDI-TOF MS characterisation, genetic diversity and antifungal susceptibility of Trichosporon species from Iranian clinical samples.
Ahangarkani F; Ilkit M; Vaseghi N; Zahedi N; Zomorodian K; Khodavaisy S; Afsarian MH; Abbasi K; de Groot T; Meis JF; Badali H
Mycoses; 2021 Aug; 64(8):918-925. PubMed ID: 33998718
[TBL] [Abstract][Full Text] [Related]
17. Molecular identification and susceptibility testing of Trichosporon isolates from a Brazilian hospital.
Araujo Ribeiro M; Alastruey-Izquierdo A; Gomez-Lopez A; Rodriguez-Tudela JL; Cuenca-Estrella M
Rev Iberoam Micol; 2008 Dec; 25(4):221-5. PubMed ID: 19071890
[TBL] [Abstract][Full Text] [Related]
18. Intergenic spacer (IGS-1) region sequence-based identification, genotypic analysis, and antifungal susceptibility of clinical Trichosporon species.
Parashar A; Rastogi V; Prakash H; Pandey A; Rudramurthy SM
Indian J Med Microbiol; 2023; 45():100390. PubMed ID: 37573054
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology and Antifungal Susceptibility of Infections Caused by
Singh S; Capoor MR; Varshney S; Gupta DK; Verma PK; Ramesh V
Indian J Med Microbiol; 2019; 37(4):536-541. PubMed ID: 32436877
[TBL] [Abstract][Full Text] [Related]
20. In Vitro Antifungal Activity of Sertraline and Synergistic Effects in Combination with Antifungal Drugs against Planktonic Forms and Biofilms of Clinical Trichosporon asahii Isolates.
Cong L; Liao Y; Yang S; Yang R
PLoS One; 2016; 11(12):e0167903. PubMed ID: 27930704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
